Trial Profile
A phase I trial evaluating the bioequivalence of biosimilar trastuzumab and Herceptin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Sep 2020
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- 26 Feb 2014 New trial record